How strong is AbbVie’s immunology franchise after Humira’s LOE?

AbbVie — once heavily reliant on its blockbuster drug Humira — appears to have not only survived Humira’s loss of exclusivity (LOE) in the U.S., but is mounting a convincing comeback. According to recent analysis from Zacks Investment Research, AbbVie’s immunology division is now being powered by two newer drugs, Skyrizi and Rinvoq — a shift that has robustly offset the decline in Humira sales and even positioned the company for future growth. Here’s the breakdown: In the first nine months of 2025, combined sales of Skyrizi and Rinvoq reached US$18.5 billion, up 53% year-over-year. The drugs have been successfully launched across key indications formerly covered by Humira — plus new uses such as atopic dermatitis — expanding their potential patient base. Given strong demand, market share gains, and a pipeline of additional indications (e.g. for Rinvoq), AbbVie projects that combined sales of Skyrizi and Rinvoq could exceed US$25 billion in 2025, with further growth expected thereafter. The shift seems to be paying off: despite Humira’s sharp sales drop post‑LOE, AbbVie’s overall immunology revenues are rebounding, giving investors confidence that the company’s “post‑Humira” strategy may well secure its long-term competitiveness. #AbbVie #Immunology #Skyrizi #Rinvoq #SlimScan #GrowthStocks #CANSLIM